miR-30-5p may represent a novel therapeutic target in NSCLC, colorectal cancer, and nasopharyngeal carcinoma since it can mitigate tumorigenesis through USP22 suppression, leading to Wnt/β‐catenin signaling target genes (Axin2 and MYC) and Sirt1/JAK/STAT3 signaling modulation [259–261]. This evidence concerns the gene MYC and nasopharyngeal carcinoma.